Literature DB >> 9802862

Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma.

M G Ewend1, P Sampath, J A Williams, B M Tyler, H Brem.   

Abstract

OBJECTIVE: Despite improved systemic control of metastatic breast cancer, the incidence of brain metastases from breast carcinoma continues to rise, in part because most systemically administered agents have poor central nervous system penetration. Therefore, as a method of optimizing drug delivery into the central nervous system, we studied the safety and efficacy of chemotherapy delivered locally via biodegradable polymers in a mouse model of breast carcinoma metastases to the brain.
METHODS: The chemotherapeutic agents carmustine (BCNU), carboplatin, and camptothecin were incorporated into controlled release polymers and tested individually against intracranial challenges of EMT-6 breast tumor in BALB/c female mice. For each drug, four groups were tested: Group 1, empty polymer (no drug); Group 2, external beam radiotherapy (XRT) alone; Group 3, local chemotherapy from biodegradable polymer alone; and Group 4, local chemotherapy and XRT together. Polymers were implanted 5 days after intracranial tumor inoculation; XRT was administered on Days 7 through 9 (300 cGy/d).
RESULTS: BCNU polymer alone (n = 10; median survival time, >200 d; P < 0.0001) and BCNU and XRT together (n = 10; median survival time, 41 d; P = 0.02) significantly improved survival in mice with intracranial EMT-6 breast cancer in comparison with control animals (n = 20; median survival time, 17 d). Carboplatin and camptothecin, either with or without XRT, and XRT alone did not have any significant effect on survival.
CONCLUSION: Local delivery of BCNU with biodegradable polymers can significantly prolong survival in a murine model of intracranial metastatic breast cancer. Surgical resection and placement of BCNU polymers into the resection cavity may decrease the incidence of local recurrence of breast cancer metastases with minimal morbidity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802862     DOI: 10.1097/00006123-199811000-00093

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

Review 1.  Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.

Authors:  H Christopher Lawson; Prakash Sampath; Eileen Bohan; Michael C Park; Namath Hussain; Alessandro Olivi; Jon Weingart; Lawrence Kleinberg; Henry Brem
Journal:  J Neurooncol       Date:  2006-12-14       Impact factor: 4.130

2.  Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.

Authors:  Urvashi M Upadhyay; Betty Tyler; Yoda Patta; Robert Wicks; Kevin Spencer; Alexander Scott; Byron Masi; Lee Hwang; Rachel Grossman; Michael Cima; Henry Brem; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

Review 3.  Preclinical approaches to study the biology and treatment of brain metastases.

Authors:  William Cruz-Muñoz; Robert S Kerbel
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

Review 4.  Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.

Authors:  Christopher Guerin; Alessandro Olivi; Jon D Weingart; H Christopher Lawson; Henry Brem
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

Review 5.  Clinical Considerations of Focal Drug Delivery in Cancer Treatment.

Authors:  Jamie Harris; Samuel C Klonoski; Bill Chiu
Journal:  Curr Drug Deliv       Date:  2017       Impact factor: 3.758

6.  Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Authors:  Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary L Affronti; Henry S Friedman
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

7.  Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.

Authors:  Yuan-Yun Tseng; Chen-Hsing Su; Shun-Tai Yang; Yin-Chen Huang; Wei-Hwa Lee; Yi-Chuan Wang; Shou-Cheng Liu; Shih-Jung Liu
Journal:  Oncotarget       Date:  2016-09-13

8.  Gliadel for brain metastasis.

Authors:  Taylor J Abel; Timothy Ryken; Maciej S Lesniak; Patrik Gabikian
Journal:  Surg Neurol Int       Date:  2013-05-02

9.  Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.

Authors:  Steven Brem; Christina A Meyers; Gary Palmer; Margaret Booth-Jones; Surbhi Jain; Matthew G Ewend
Journal:  Cancer       Date:  2013-08-23       Impact factor: 6.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.